Detalhe da pesquisa
1.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med
; 384(13): 1216-1226, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789010
2.
Genetic Markers Among the Israeli Druze Minority Population With End-Stage Kidney Disease.
Am J Kidney Dis
; 83(2): 183-195, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717846
3.
Obstetrical outcomes of women with new-onset isolated proteinuria diagnosed after 24 weeks' gestation.
Arch Gynecol Obstet
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739292
4.
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Am J Kidney Dis
; 81(2): 145-155.e1, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35843439
5.
Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1.
Pediatr Nephrol
; 38(6): 1811-1820, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36449101
6.
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
Pediatr Nephrol
; 38(4): 1075-1086, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913563
7.
["AN UNFINISHED SYMPHONY": MEDICINE DURING THE WARSAW GHETTO UPRISING].
Harefuah
; 162(4): 252-256, 2023 Apr.
Artigo
em Hebraico
| MEDLINE | ID: mdl-37120747
8.
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Genet Med
; 24(3): 654-662, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906487
9.
[RASBURICASE TREATMENT FOR NEONATAL ACUTE KIDNEY INJURY - A CASE REPORT].
Harefuah
; 160(12): 806-809, 2021 Dec.
Artigo
em Hebraico
| MEDLINE | ID: mdl-34957716
10.
Chronic health conditions in Jewish Holocaust survivors born during World War II.
Isr Med Assoc J
; 17(4): 206-12, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040044
11.
Diagnostic Utility of Exome Sequencing Among Israeli Children With Kidney Failure.
Kidney Int Rep
; 8(10): 2126-2135, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850020
12.
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Kidney Int Rep
; 7(3): 494-506, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257062
13.
Wilms' tumor gene 1: a possible new proangiogenic factor in Hodgkin lymphoma.
Appl Immunohistochem Mol Morphol
; 21(2): 177-80, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22688351